## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

es)		1											
1. Name and Address of Reporting Person* Werner Milton H.			2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]						5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  X Director X 10% Owner				
(Last) (First) (Middle) 3350 RIVERWOOD PARKWAY SE, SUITE 1900				3. Date of Earliest Transaction (Month/Day/Year) 05/27/2022					X Officer (give title below) Other (specify below) President and CEO				
(Street) ATLANTA, GA 30339			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(State)	(Zip)	Т	able I -	Non	-Deriva	tive S	ecurities	Acqui	red, Disp	osed of, or l	Beneficially (	Owned	
	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, it	3. Transaction Code (Instr. 8)		tion 4.	4. Securities Acquired		uired of (D)	d 5. Amount of Securities		ies Following	6. Ownership Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)  Code V Amount (D)		or	Price				Ownership (Instr. 4)				
	05/27/2022		P		5,	,000			5,330,4	33		D	
	Table II -	Derivative Securi	ies Acq	1	the for	m dis	plays a	curren	itly valid	OMB con			
la =	la	<del>```</del>									l	0.110	Leave
on Date	Execution Date, any	ate, if Transaction Code	e, if Transaction Code of (Instr. 8) Derivative Securitie Acquires (A) or Disposed of (D) (Instr. 3,		and Expiration Date (Month/Day/Year)		Amo Unde Secur	unt of erlying rities	8. Price of Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivati Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)	
					Date	1	Expiration	n	Amount or Number				
,	(Street)  OD PARKW.  (Street)  OState)  separate line for the part of the part	(Street)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Street)  OB PARKWAY SE, SUITE  (Street)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Street)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Month/Day/Year)  OB PARKWAY SE, SUITE  (Month/Day/Year)	2. Issuer Name a Inhibikase The Inhibitation Inhibikase The Inhibitation	2. Issuer Name and Tic Inhibikase Therapeur (First) (Middle) (Middle) (Street) 3. Date of Earliest Transa (05/27/2022) 4. If Amendment, Date (Ostate) (Zip) Table I -  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) (e.g., puts, calls, warrants (e.g., puts, calls, warrants (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 8) (Instr. 8)	2. Issuer Name and Ticker of Inhibikase Therapeutics.  (First) (Middle) 3. Date of Earliest Transaction 05/27/2022  (Street) 4. If Amendment, Date Origin 0339  (State) (Zip) Table I - Non Execution Date, if (Month/Day/Year) 2A. Deemed Execution Date, if (Instr. 8) 2A. Deemed Execution Date, if (Month/Day/Year) 2A. Deemed Execution Date, if (Month/Day/Year) 2A. Deemed Execution Date, if (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year) 3A.	2. Issuer Name and Ticker or Tradin Inhibikase Therapeutics, Inc. [  (First) (Middle) (Middle) (Middle) (Month Day Year)  (Street) 4. If Amendment, Date Original Filed (Month/Day/Year)  (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, doing to make the property of the perivative Securities Acquired (A) or Disposed of (D) (Instr. 3, doing the perivative).	2. Issuer Name and Ticker or Trading Syr Inhibikase Therapeutics, Inc. [IKT]  3. Date of Earliest Transaction (Month/Day 05/27/2022  (Street)  4. If Amendment, Date Original Filed(Month 0339  (State)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date Execution Date, if (Month/Day/Year)  2. Transaction Execution Date, if (Month/Day/Year)  3. Transaction Execution Date, if (Linstr. 8)  Code (Instr. 8)  Persons wh contained ir the form dis  Table II - Derivative Securities Acquired, Disposed of (Execution Date, if (Month/Day/Year))  3. Transaction Execution Date, if (Instr. 8)  Code (Instr. 8)  Code (Instr. 8)  Persons wh contained ir the form dis  Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8)  (Instr. 3)	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]  (First) (Middle) (D PARKWAY SE, SUITE)  (Street) 4. If Amendment, Date Original Filed(Month/Day/Year)  (State) (Zip) Table I - Non-Derivative Securities  (Month/Day/Year) 2. Transaction Date (Month/Day/Year)  (State) (Zip) Table I - Non-Derivative Securities Execution Date, if (Month/Day/Year)  (Month/Day/Year) Code (A) or Disposed of (Instr. 3, 4 and 5)  (A) or (Code V Amount (D) (D)  (State) Persons who responsion the form displays a  Table II - Derivative Securities Acquired, Disposed of, or Ben (e.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities Acquired (A) or Disposed of (D) (Instr. 3), and the convertible securities (A) or Disposed of (D) (Instr. 3), and the convertible securities (A) or Disposed of (D) (Instr. 3), and the convertible securities (A) or Disposed of (D) (Instr. 3), and the convertible securities (D) (Instr. 3), and the convertible securities (D) (Instr. 4) (Instr. 4) (In	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]   S. Relation Inhibikase Therapeutics, Inc. [IKT]   S. Direction (First) (Middle) (DPARKWAY SE, SUITE   O5/27/2022   O	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]   S. Relationship of Reg (Chapter (Irist)) (Middle)   D. PARKWAY SE, SUITE   3. Date of Earliest Transaction (Month/Day/Year)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by More than (Instr. 3)   G. Individual or Joint/ X. Form filed by Mor	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]  (First) (Middle) (DPARKWAY SE, SUITE)  3. Date of Earliest Transaction (Month/Day/Year)  (Street) 4. If Amendment, Date Original Filed(Month/Day/Year)  (State) 2. Transaction Date (Image) (Month/Day/Year)  (State) 2. Transaction Date (Month/Day/Year)  (State) 2. Transaction Date (Month/Day/Year)  (Month/Day/Year) 2. Transaction Date (Month/Day/Year)  (Month/Day/Year) 3. Transaction Date (Gode (A) or Disposed of (D) (Instr. 3, 4 and 5)  (Instr. 3 and 4)  (Month/Day/Year) 3. Transaction Date (Gode (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 3. Transaction Date (Gode (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 3. Transaction Date (Gode (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 3. Transaction Date (Gode (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3)  (Instr. 3 and 4)  (Month/Day/Year) 5. Amount of Securities Menetically Owned Following Reported Transaction(S)  (Instr. 3 and 4)  (Instr. 3 and 4)  (Month/Day/Year) 5. Amount of Securities Menetically Owned Following Reported Transaction (Instr. 4)  (Month/Day/Year) 6. Date Exercisable and Execution of Information Contained in this form aurernot required to respond unlet the form displays acurrently valid OMB control number of Code (Month/Day/Year)  (Month/Day/Year) (Instr. 3)  (Month/Day/Year) (Instr. 3)	2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]   3. Date of Earliest Transaction (Month/Day/Year)   3. Date of Earliest Transaction (Month/Day/Year)   5. Relationship of Reporting Person(s) to Issuer X_Director X_Direc

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Werner Milton H. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA, GA 30339	X	X	President and CEO		

### **Signatures**

/s/ Milton H. Werner	05/31/2022		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.